Dudediligence.

Anixa Biosciences, Inc

ANIXNASDAQ · Pharmaceutical Preparations
Write an idea

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

34.6M

on 2026-07-31, from 32.0M on 2024-04-30 10-Q ↗

10M20M30MApr2024JulOctJan2025AprJulOctJan2026AprJul

Newest

$200.0M

S-3 of 2025-09-10. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗

$100.0M

Cantor Fitzgerald, agreement of 2025-09-10. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗

Warrants

300K

Priced warrants: 300K at $6.56, 2026-07-31. 10-Q ↗

Cash

7.5 quarters

$13.9M on 2026-07-31 ÷ $1.8M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised: 1 of its filings are not read yet.